Mindray(SZ:300760) Ge Long Hui·2025-10-14 07:38Core Insights - Company anticipates that by the first half of 2025, international revenue will account for approximately 50% of total revenue, with international in vitro diagnostics contributing 29% and high-potential segments like international animal healthcare and minimally invasive surgery making up 12% of international revenue [1][2] - The company has been actively pursuing overseas markets for 25 years, aiming for international revenue to eventually reach 70% of total revenue, with current international market share at only 2-3% [2] - The company is focusing on deeper localization strategies to meet high-end customer demands and local government requirements, with plans for localized production bases in 14 countries, 11 of which have already commenced production [2] Market Position and Strategy - The company believes that the international market size is significantly larger than the domestic market, justifying the expectation for international revenue to exceed 50% of total revenue [2] - The company emphasizes the importance of adapting to changing international conditions and leveraging its experience and resources to seize potential opportunities [3] - The company maintains confidence in its ability to deliver stable operating performance and healthy profit levels, which are essential for long-term investor returns and market recognition [3]